Table 2 Adverse reactions to peanut OIT on initial escalation day (Day 1)

Total no. of doses of OIT, n

36

18

Total no. of patients reporting symptoms

3/4

2/2

Total no. of doses with symptoms, n (% of total OIT doses)

8/36 (22%)

12/18 (67%)

Anaphylaxis, n (% of total OIT doses)

-*

1 (5%)

Symptoms n, (% of OIT doses)

Ketotifen

Placebo

Gastrointestinal

6/36 (17%)

11/18 (61%)

Cutaneous

-

1/18 (6%)

Lower respiratory

2/36 (6%)

1/18 (6%)

Oropharyngeal

-

2/18 (11%)

Upper respiratory

-

-

Cardiovascular

-

-

Other^A

-

2/18 (11%)

Treatment n, (% of OIT doses)

Ketotifen

Placebo

Epinephrine

-

-

Diphenhydramine

-

-

Cetirizine or other**

-

1/18 (6%)

Prednisone

-

-

Salbutamol or other inhaled medication

-

1/18 (6%)